vs
ARTIVION, INC.（AORT）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Rocket Lab Corp的季度营收约是ARTIVION, INC.的1.5倍（$179.7M vs $116.0M），ARTIVION, INC.净利率更高（2.1% vs -29.5%，领先31.5%），Rocket Lab Corp同比增速更快（35.7% vs 19.2%），ARTIVION, INC.自由现金流更多（$-7.9M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 9.1%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
AORT vs RKLB — 直观对比
营收规模更大
RKLB
是对方的1.5倍
$116.0M
营收增速更快
RKLB
高出16.5%
19.2%
净利率更高
AORT
高出31.5%
-29.5%
自由现金流更多
AORT
多$106.2M
$-114.2M
两年增速更快
RKLB
近两年复合增速
9.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $179.7M |
| 净利润 | $2.4M | $-52.9M |
| 毛利率 | 63.1% | 38.0% |
| 营业利润率 | 9.2% | -28.4% |
| 净利率 | 2.1% | -29.5% |
| 营收同比 | 19.2% | 35.7% |
| 净利润同比 | 114.7% | -1.1% |
| 每股收益（稀释后） | $0.06 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTRKLB
| Q4 25 | $116.0M | $179.7M | ||
| Q3 25 | $113.4M | $155.1M | ||
| Q2 25 | $113.0M | $144.5M | ||
| Q1 25 | $99.0M | $122.6M | ||
| Q4 24 | $97.3M | $132.4M | ||
| Q3 24 | $95.8M | $104.8M | ||
| Q2 24 | $98.0M | $106.3M | ||
| Q1 24 | $97.4M | $92.8M |
净利润AORTRKLB
| Q4 25 | $2.4M | $-52.9M | ||
| Q3 25 | $6.5M | $-18.3M | ||
| Q2 25 | $1.3M | $-66.4M | ||
| Q1 25 | $-505.0K | $-60.6M | ||
| Q4 24 | $-16.5M | $-52.3M | ||
| Q3 24 | $-2.3M | $-51.9M | ||
| Q2 24 | $-2.1M | $-41.6M | ||
| Q1 24 | $7.5M | $-44.3M |
毛利率AORTRKLB
| Q4 25 | 63.1% | 38.0% | ||
| Q3 25 | 65.6% | 37.0% | ||
| Q2 25 | 64.7% | 32.1% | ||
| Q1 25 | 64.2% | 28.8% | ||
| Q4 24 | 63.2% | 27.8% | ||
| Q3 24 | 63.7% | 26.7% | ||
| Q2 24 | 64.6% | 25.6% | ||
| Q1 24 | 64.6% | 26.1% |
营业利润率AORTRKLB
| Q4 25 | 9.2% | -28.4% | ||
| Q3 25 | 11.1% | -38.0% | ||
| Q2 25 | 7.4% | -41.3% | ||
| Q1 25 | 2.2% | -48.3% | ||
| Q4 24 | 2.7% | -38.9% | ||
| Q3 24 | 4.6% | -49.5% | ||
| Q2 24 | 6.6% | -40.7% | ||
| Q1 24 | 26.0% | -46.4% |
净利率AORTRKLB
| Q4 25 | 2.1% | -29.5% | ||
| Q3 25 | 5.7% | -11.8% | ||
| Q2 25 | 1.2% | -46.0% | ||
| Q1 25 | -0.5% | -49.5% | ||
| Q4 24 | -16.9% | -39.5% | ||
| Q3 24 | -2.4% | -49.6% | ||
| Q2 24 | -2.2% | -39.2% | ||
| Q1 24 | 7.7% | -47.7% |
每股收益（稀释后）AORTRKLB
| Q4 25 | $0.06 | $-0.09 | ||
| Q3 25 | $0.13 | $-0.03 | ||
| Q2 25 | $0.03 | $-0.13 | ||
| Q1 25 | $-0.01 | $-0.12 | ||
| Q4 24 | $-0.40 | $-0.11 | ||
| Q3 24 | $-0.05 | $-0.10 | ||
| Q2 24 | $-0.05 | $-0.08 | ||
| Q1 24 | $0.18 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $1.0B |
| 总债务越低越好 | $215.1M | $152.4M |
| 股东权益账面价值 | $448.2M | $1.7B |
| 总资产 | $884.8M | $2.3B |
| 负债/权益比越低杠杆越低 | 0.48× | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资AORTRKLB
| Q4 25 | $64.9M | $1.0B | ||
| Q3 25 | $73.4M | $976.7M | ||
| Q2 25 | $53.5M | $688.1M | ||
| Q1 25 | $37.7M | $428.4M | ||
| Q4 24 | $53.5M | $419.0M | ||
| Q3 24 | $56.2M | $442.4M | ||
| Q2 24 | $55.0M | $496.8M | ||
| Q1 24 | $51.1M | $492.5M |
总债务AORTRKLB
| Q4 25 | $215.1M | $152.4M | ||
| Q3 25 | $214.9M | $347.0M | ||
| Q2 25 | $215.6M | $346.5M | ||
| Q1 25 | $314.7M | $345.9M | ||
| Q4 24 | $314.3M | $345.4M | ||
| Q3 24 | $314.0M | $61.2M | ||
| Q2 24 | $313.6M | $64.2M | ||
| Q1 24 | $313.3M | $66.8M |
股东权益AORTRKLB
| Q4 25 | $448.2M | $1.7B | ||
| Q3 25 | $438.7M | $1.3B | ||
| Q2 25 | $419.9M | $688.5M | ||
| Q1 25 | $294.3M | $431.3M | ||
| Q4 24 | $276.2M | $382.5M | ||
| Q3 24 | $304.7M | $419.8M | ||
| Q2 24 | $295.1M | $455.2M | ||
| Q1 24 | $295.0M | $478.9M |
总资产AORTRKLB
| Q4 25 | $884.8M | $2.3B | ||
| Q3 25 | $857.7M | $2.2B | ||
| Q2 25 | $838.4M | $1.6B | ||
| Q1 25 | $791.2M | $1.3B | ||
| Q4 24 | $789.1M | $1.2B | ||
| Q3 24 | $803.1M | $1.2B | ||
| Q2 24 | $789.5M | $1.2B | ||
| Q1 24 | $784.0M | $1.2B |
负债/权益比AORTRKLB
| Q4 25 | 0.48× | 0.09× | ||
| Q3 25 | 0.49× | 0.27× | ||
| Q2 25 | 0.51× | 0.50× | ||
| Q1 25 | 1.07× | 0.80× | ||
| Q4 24 | 1.14× | 0.90× | ||
| Q3 24 | 1.03× | 0.15× | ||
| Q2 24 | 1.06× | 0.14× | ||
| Q1 24 | 1.06× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $-114.2M |
| 自由现金流率自由现金流/营收 | -6.9% | -63.6% |
| 资本支出强度资本支出/营收 | 23.7% | 27.6% |
| 现金转化率经营现金流/净利润 | 8.06× | — |
| 过去12个月自由现金流最近4个季度 | $839.0K | $-321.8M |
8季度趋势，按日历期对齐
经营现金流AORTRKLB
| Q4 25 | $19.6M | $-64.5M | ||
| Q3 25 | $22.3M | $-23.5M | ||
| Q2 25 | $15.0M | $-23.2M | ||
| Q1 25 | $-17.0M | $-54.2M | ||
| Q4 24 | $10.1M | $-2.4M | ||
| Q3 24 | $11.5M | $-30.9M | ||
| Q2 24 | $6.1M | $-13.0M | ||
| Q1 24 | $-5.5M | $-2.6M |
自由现金流AORTRKLB
| Q4 25 | $-7.9M | $-114.2M | ||
| Q3 25 | $17.7M | $-69.4M | ||
| Q2 25 | $11.7M | $-55.3M | ||
| Q1 25 | $-20.6M | $-82.9M | ||
| Q4 24 | $8.7M | $-23.9M | ||
| Q3 24 | $7.8M | $-41.9M | ||
| Q2 24 | $3.6M | $-28.3M | ||
| Q1 24 | $-9.1M | $-21.8M |
自由现金流率AORTRKLB
| Q4 25 | -6.9% | -63.6% | ||
| Q3 25 | 15.6% | -44.8% | ||
| Q2 25 | 10.4% | -38.3% | ||
| Q1 25 | -20.8% | -67.6% | ||
| Q4 24 | 9.0% | -18.1% | ||
| Q3 24 | 8.2% | -40.0% | ||
| Q2 24 | 3.7% | -26.7% | ||
| Q1 24 | -9.3% | -23.5% |
资本支出强度AORTRKLB
| Q4 25 | 23.7% | 27.6% | ||
| Q3 25 | 4.1% | 29.6% | ||
| Q2 25 | 2.9% | 22.2% | ||
| Q1 25 | 3.7% | 23.4% | ||
| Q4 24 | 1.5% | 16.3% | ||
| Q3 24 | 3.8% | 10.5% | ||
| Q2 24 | 2.6% | 14.4% | ||
| Q1 24 | 3.7% | 20.7% |
现金转化率AORTRKLB
| Q4 25 | 8.06× | — | ||
| Q3 25 | 3.42× | — | ||
| Q2 25 | 11.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.73× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
